15Feb 2025
PPP2R1A Mutations Enhance ATR Inhibitor Sensitivity in OCCC

PPP2R1A Mutations Enhance ATR Inhibitor Sensitivity in OCCC

The research identifies that the inactivation of protein phosphatase 2A (PP2A) subunits, including PPP2R1A, enhances ATR inhibitor (ATRi) sensitivity in ARID1A mutant OCCC. Analysis of patient cohorts revealed that 52% of OCCC cases possess oncogenic PPP2R1A mutations. In vitro and in vivo models showed that PPP2R1A mutations lead to genomic instability and ATRi sensitivity, suggesting PPP2R1A mutations as a biomarker for ATRi therapy.

  • #oncology

Like

Save

Share